Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 

🌟 Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 🌟

Gastrointestinal Tumor

Chinese biotech company CARsgen Therapeutics unveiled the latest data for its targeted Claudin18.2 autologous CAR-T cell candidate product, CT041, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This therapy is specifically designed for Claudin18.2-positive solid tumors, such as gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic cancer.

🔬 **About CT041**

CT041 (satricabtagene autoleucel, satri-cel) is a groundbreaking CAR-T cell therapy undergoing multiple clinical trials in both China and the United States. Since 2022, it has received RMAT designation and orphan drug status from the FDA, and PRIME designation from the EMA.

📊 **Clinical Trial Highlights**

Between March 2019 and January 2024, a total of 98 patients participated in the Phase 1 trial of CT041. The trial results indicated:

– **Safety**: The most common adverse events were hematologic toxicities related to lymphocyte depletion, with no dose-limiting toxicities or treatment-related deaths reported.

– **Efficacy**: The overall objective response rate (ORR) was 37.8%, and the disease control rate (DCR) was 75.5%. The median progression-free survival (PFS) was 4.4 months, and the median overall survival (OS) was 8.4 months.

For gastric cancer patients, the results were even more remarkable:

– **ORR**: 57.4%

– **DCR**: 83.0%

– **Median PFS**: 5.8 months

– **Median OS**: 9.7 months

🎯 **Future Outlook**

CT041 has demonstrated promising safety and highly encouraging efficacy in heavily pretreated Claudin18.2-positive advanced gastrointestinal cancer patients. This breakthrough brings new hope and treatment options for patients with gastrointestinal tumors.

Follow us for more updates on the latest medical breakthroughs! 💡🌐

Whatsapp：+8613717959070
Email: doctor.huang@globecancer.com

#MedicalBreakthrough #CancerTreatment #CAR_T #CT041 #GastricCancer #PancreaticCancer #CARsgenTherapeutics #ASCO2024 #MedicalAdvances #CARsgen